1. Patients with multiple myeloma treated with high-dose chemotherapy and autologous stem-cell transplantation consolidation therapy had significantly longer disease-free survival, overall survival, and hematologic adverse events compared to those treated with a combination of melphalan, prednisone, and lenalidomide.
2. Patients treated with lenalidomide maintenance therapy had a significantly longer disease-free survival but not a significantly improved overall survival compared to patients treated with no maintenance therapy.
Evidence Rating Level: 1 (Excellent)
Study Rundown: The current standard of therapy for newly diagnosed multiple myeloma in patients under 65 years of age is high-dose chemotherapy plus autologous stem-cell transplantation. This regimen has been shown to prolong progression-free survival and overall survival in these patients. Given the recent success of immunomodulatory drugs in treating patients with multiple myeloma, there has been growing interest in comparing the standard treatment to the newer and less toxic, oral medications.
In this open-label, randomized study, patients under 65 years of age with newly diagnosed multiple myeloma were treated with one of two consolidation therapies: high-dose melphalan plus autologous stem-cell transplantation or a combination of melphalan-prednisone-lenalidomide (MPR). Patients in the high-dose chemotherapy and stem-cell transplant group had significantly longer progression-free survival and improved 4-year overall survival, but also had significantly higher numbers of adverse events including neutropenia, thrombocytopenia, and infections. The authors also compared maintenance therapy with lenalidomide versus no maintenance therapy and found that the former group had a significantly longer progression-free survival, though there was no significant difference in overall survival rates. There were also significantly higher levels of adverse events including neutropenia and infections in the lenalidomide maintenance therapy group.
The greatest strength of this study is the use of a well-powered randomized study design to address an important clinical question in the management of newly diagnosed multiple myeloma. Major drawbacks include the fact that only 68% of the originally enrolled subjects were eligible for randomization to the consolidation therapy groups, largely due to inadequate induction therapy responses. This means that the final study population is biased towards patients with treatment-responsive multiple myeloma. Secondly, the study does not address the efficacy of bortezomib, a proteasome inhibitor that has shown utility in the treatment of multiple myeloma.
Click to read the study, published today in NEJM
Click to read the accompanying editorial in NEJM
Relevant Reading: A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Dr. Antonio Palumbo, Chief of the Myeloma Unit of the Department of Oncology, Division of Hematology, University of Torino, talks to 2 Minute Medicine:
“In the era of novel, effective agents, autologous stem cell transplantation confirmed its superiority over chemotherapy with novel agents in young patients (< 65 years of age) with multiple myeloma, prolonging both progression-free survival and overall survival. Therefore, transplantation should be used at diagnosis, and not delayed until relapse as is currently done in several centers.
In addition, maintenance therapy with lenalidomide further improved progression-free survival and marginally overall survival. Thus, the optimal strategy for young patients is a sequential approach that includes induction with novel agents, followed by transplantation and then maintenance therapy.”
In-Depth [randomized controlled trial]: This open-label, randomized phase 3 study compared high-dose melphalan, a chemotherapeutic agent, plus autologous stem-cell transplantation with a combination of melphalan-prednisone-lenalidomide (MPR) for consolidation therapy in the treatment of newly diagnosed multiple myeloma. The study also compared lenalidomide (an immunomodulatory drug) maintenance therapy with no maintenance therapy. The study included patients with newly diagnosed multiple myeloma who were 65 years of age or younger. 402 patients were enrolled, though only 273 (68%) were eligible to undergo randomization to one of the consolidation therapy treatment arms following induction therapy. The primary outcome was progression-free survival; secondary end points included overall survival, overall response rate, time to response, and safety.
In intention-to-treat analyses, the median progression-free survival was significantly longer among patients in the high-dose melphalan and stem-cell transplantation group compared to those in the MPR group (43.0 months versus 22.4 months; P<0.001). High-dose melphalan and stem-cell transplantation was also associated with a better 4-year overall survival rate (81.6% vs. 65.3%; P=0.02). Median progression-free survival was significantly longer in the lenalidomide maintainence therapy group compared to the no maintenance therapy group (41.9 months vs. 21.6 months; P<0.001). However, there was no statistically significant difference in overall survival between the maintenance therapy comparison groups.
In terms of safety, hematologic adverse events such as neutropenia and thrombocytopenia were significantly more likely in patients treated with high-dose melphalan and stem-cell transplantation compared to MPR (P<0.001 for both comparisons); GI events, infections, and systemic events were also significantly more common. In the maintenance phase, neutropenia, infections, and dermatologic events were more likely in patients treated with lenalidomide.
More from this author: Combination CPAP, weight loss for obstructive sleep apnea offer no added benefit, Tofacitinib superior to methotrexate monotherapy for rheumatoid arthritis, Gene mutation associated with antimalarial resistance across Southeast Asia, Moderate sodium intake optimal for cardiovascular health, Transfusion therapy linked with reduced neurovascular disease in sickle cell anemia
Image: CC/Wiki
©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.
